A study of 56 adults treated for severe H1N1 influenza A in an ICU at one of 25 Canadian centers found a triple dose of oseltamivir increased the speed of viral clearance, compared with standard therapy. ICU physician Anand Kumar, who presented the study at the Interscience Conference on Antimicrobial Agents and Chemotherapy, said another potential benefit to higher dosage therapy may be reducing the duration of infection control and patient isolation measures.

Related Summaries